News
![DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
DGAP-News: Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference
![DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
DGAP-News: Abivax präsentiert auf der J.P. Morgan 40th Annual Healthcare Conference
![DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis](/assets/news/news6-ad07925a95156ae03dbe17caf44a9dc29f254ff2c2a42c7678d35288ad55cec8.png)
DGAP-News: Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis
![DGAP-News: Abivax erhält Feedback der US-Amerikanischen Zulassungsbehörde mit Guidance zur Überführung von ABX464 in die klinische Phase-3-Testung](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
DGAP-News: Abivax erhält Feedback der US-Amerikanischen Zulassungsbehörde mit Guidance zur Überführung von ABX464 in die klinische Phase-3-Testung
![DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
DGAP-News: Abivax's phase 1/2 clinical study results of ABX196 in liver cancer show good tolerability and promising signals of clinical benefit and were selected for presentation at the ASCO GI Cancers Symposium
![DGAP-News: Abivax' Phase-1/2-Studienergebnisse mit ABX196 zur Behandlung von Leberkrebs zeigen gute Sicherheit und vielversprechende Anzeichen klinischen Nutzens ...](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
DGAP-News: Abivax' Phase-1/2-Studienergebnisse mit ABX196 zur Behandlung von Leberkrebs zeigen gute Sicherheit und vielversprechende Anzeichen klinischen Nutzens ...
![Top 4 Large-Cap Stocks With Major Short Interest: https://www.marketbeat.com/logos/articles/med_20240612135212_top-4-large-cap-stocks-with-major-short-interest.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBL0MzYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fd73e6ecda60bcc7a89c98c34810a55e3f720440/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240612135212_top-4-large-cap-stocks-with-major-short-interest.jpg?locale=us)
Top 4 Large-Cap Stocks With Major Short Interest
With the ongoing GameStop saga reigniting interest in meme stocks, investors, or more likely traders and speculators, are once again seeking out stocks with high short interest. As the overall
![Can Viking Holdings Extend Gains from Affluent Cruisers?: https://www.marketbeat.com/logos/articles/med_20240610131935_can-viking-holdings-extend-its-gains-from-affluent.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNzYyYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3da5b8b2f445eb591e288ca7ab08918ad091c911/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240610131935_can-viking-holdings-extend-its-gains-from-affluent.jpg?locale=us)
Can Viking Holdings Extend Gains from Affluent Cruisers?
Destination-focused luxury cruise operator Viking Holdings Ltd. (NYSE: VIK) went public through a $1.8 billion initial public offering (IPO) on May 1, 2024. It was priced at $24 and hasn’t
![Geron Corporation: FDA Approval Fuels Stock Price Surge: https://www.marketbeat.com/logos/articles/med_20240607114957_geron-corporation-fda-approval-fuels-stock-price-s.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN215YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--249b232b1dc3b363e2e50502a308cb8a8658a02b/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240607114957_geron-corporation-fda-approval-fuels-stock-price-s.jpg?locale=us)
Geron Corporation: FDA Approval Fuels Stock Price Surge
The recent FDA approval of RYTELO™ (imetelstat) has propelled Geron Corporation (NASDAQ: GERN) into the spotlight, sparking a surge in Geron’s stock price and attracting heightened attention
![Novavax Stock’s Recent Surge and Future Potential: https://www.marketbeat.com/logos/articles/med_20240606112435_novavax-stocks-recent-surge-and-future-potential.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM3F4YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ab2cce4c948a26cf8df4e6f082f5e00abc61ffc1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240606112435_novavax-stocks-recent-surge-and-future-potential.jpg?locale=us)
Novavax Stock’s Recent Surge and Future Potential
Novavax (NASDAQ: NVAX) is a drug and vaccine manufacturer in the healthcare sector known for its efforts in the COVID-19 vaccine market. Novavax’s stock price has experienced a remarkable surge
![Solarzellen von CESI liefern Strom für die Satelliten des globalen Internets: https://www.irw-press.at/prcom/images/messages/2024/74339/CESI_240424_DEPRconm.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeFovYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--441b69fbfd2308dd045ae58cf5943547972a28b1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/CESI_240424_DEPRconm.001.jpeg?locale=us)
Solarzellen von CESI liefern Strom für die Satelliten des globalen Internets
MAILAND, ITALIEN / ACCESSWIRE / 24. April 2024 / Die italienische Gruppe CESI hat mit einem der weltweit führenden Herstellern von Raumfahrtsystemen einen Vertrag abgeschlossen, der Optionen
![CESI Solar Cells Fuels the Satellites of the Global Internet: https://www.irw-press.at/prcom/images/messages/2024/74339/CESI_240424_ENPRcom.001.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeGQvYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--60b7d54c9d4154c0ab8e83ef6de60c2b0a2ed52f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/CESI_240424_ENPRcom.001.jpeg?locale=us)
CESI Solar Cells Fuels the Satellites of the Global Internet
MILAN, ITALY / ACCESSWIRE / April 24, 2024 / The Italian group CESI has secured a contract, with options valued at over one hundred million euros over five years, with one of the world's
![Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?: https://www.marketbeat.com/logos/articles/med_20240421181833_charts-lly.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeXg4YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dd8c2ba6e5323ef28e176a02577fb376fb8e136e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240421181833_charts-lly.jpg?locale=us)
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
The GLP-1 weight loss trend continues to flourish, and the ante keeps rising. The reigning champions in the battle of the bulge are Novo Nordisk A/V (NYSE: NVO) with its Semaglutide medications
![Akebia Therapeutics Surges on FDA Approval for Anemia Treatment: https://www.marketbeat.com/logos/articles/med_20240331142316_untitledchart-akd.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNU5wYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--56154e370edb0db76935de2e3b68d3731ccb9fe0/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240331142316_untitledchart-akd.jpg?locale=us)
Akebia Therapeutics Surges on FDA Approval for Anemia Treatment
Akebia Therapeutics Inc. (NASDAQ: AKBA) is a biopharmaceutical company specializing in developing treatments for chronic kidney diseases (CKD) and anemia management for patients with CKD. The
![5 Stocks with Unusually Large Short Interest: https://www.marketbeat.com/logos/articles/med_20240307141801_5-stocks-with-unusually-large-short-interest.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN0ZPYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--93cbfada310662b5c1c47556f7d5a9cef0a68dd1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240307141801_5-stocks-with-unusually-large-short-interest.jpg?locale=us)
5 Stocks with Unusually Large Short Interest
With the broader market reaching new all-time highs, primarily driven by the tech sector and specifically semiconductor stocks fueled by the hype surrounding AI, the spotlight is once again
![Novavax’s dispute resolution and upcoming earnings call: https://www.marketbeat.com/logos/articles/med_20240222142457_novavaxs-dispute-resolution-and-upcoming-earnings.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM0k5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--03dff2262d97f7d522f9492197704d486ee848e9/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240222142457_novavaxs-dispute-resolution-and-upcoming-earnings.jpg?locale=us)
Novavax’s dispute resolution and upcoming earnings call
Novavax (NASDAQ: NVAX) is a biotechnology pioneer dedicated to developing innovative vaccines against serious infectious diseases. Their unique approach utilizes protein-based technology, an
![Analysts see over 50% gains in these 2 mid-cap biotech stocks: https://www.marketbeat.com/logos/articles/med_20240214075553_analysts-see-over-50-gains-in-these-2-mid-cap-biot.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN3N5YkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--48eba343d55323cc51dbade828ae7ba56a5f4cb6/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240214075553_analysts-see-over-50-gains-in-these-2-mid-cap-biot.jpg?locale=us)
Analysts see over 50% gains in these 2 mid-cap biotech stocks
2024 is shaping up to be a pivotal year for the biotechnology industry.
In recent years, emergency Covid vaccines have ushered in several groundbreaking innovations that have changed the way
![3 mid-caps under $20 that Wall Street loves: https://www.marketbeat.com/logos/articles/med_20240122191242_3-mid-caps-under-20-that-wall-street-loves.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOVFUYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--39856908cabc8ed79cba37b4b804a0473a9ba5e2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240122191242_3-mid-caps-under-20-that-wall-street-loves.jpg?locale=us)
3 mid-caps under $20 that Wall Street loves
Just three trading weeks into the new year, a half dozen U.S. mid- or large-cap stocks are already up 20% or more.
Picking up where it left off last year, artificial intelligence (AI) data center
![2 biotechs with promising weight-loss drugs coming: https://www.marketbeat.com/logos/articles/med_20240114165130_chart-vktx2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFVNYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1beeff80657e84dcfd835627b1cd6ada42ca6d43/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240114165130_chart-vktx2.jpg?locale=us)
2 biotechs with promising weight-loss drugs coming
Clinical weight-loss medications have been making headlines. GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co. (NYSE: LLY) owned Mounjaro and Zepbound
![Voyager Therapeutics stock pops 30% on deal with Novartis: https://www.marketbeat.com/logos/articles/med_20240108080612_voyager-therapeutics-pops-30-on-gene-therapy-deal.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBOWdFYkE9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d6d8cf733f50b87149bec09f287b00c8d609fb8c/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20240108080612_voyager-therapeutics-pops-30-on-gene-therapy-deal.jpg?locale=us)
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took a 30% spike on news of its partnership with
![2 gene-editing stocks reshaping hereditary disease treatments: https://www.marketbeat.com/logos/articles/med_20231231121858_chart-ntla.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNkgrYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--d8cf7f26c4d9caf0889b2db456211e7f76836263/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231231121858_chart-ntla.jpg?locale=us)
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal Drug Administration (FDA) approved a
![3 Dividend Champions with room for dividend growth: https://www.marketbeat.com/logos/articles/med_20231110113832_3-dividend-champions-with-room-for-dividend-growth.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBd0RUYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fbf06ab40dff23457a16966fc5b6eb94f89bb974/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20231110113832_3-dividend-champions-with-room-for-dividend-growth.jpg?locale=us)
3 Dividend Champions with room for dividend growth
The World Series champion Texas Rangers recently paid nice dividends for sports bettors. For stock investors, there's a different, more predictable group of dividend payers worth betting on — the
![2 Stocks That Doubled EPS Estimates and Flashing Buy Signals: https://www.marketbeat.com/logos/articles/med_20230827122241_chart-edr2.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMmVFYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b90155622a620fcdbed67112976eb3db92cedf09/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230827122241_chart-edr2.jpg?locale=us)
2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with upcoming catalysts to watch. These
![Saturn Oil & Gas Inc. meldet Finanz- und Betriebsergebnisse für das zweite Quartal 2023 mit Rekordzahlen bei der Quartalsproduktion und dem bereinigten Cashflow: https://www.irw-press.at/prcom/images/messages/2023/71644/Saturn_081423_DEPRcom.003.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNTl5YXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a5935e64bff34fc0331513331ace23ff55270f2a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_081423_DEPRcom.003.png?locale=us)
Saturn Oil & Gas Inc. meldet Finanz- und Betriebsergebnisse für das zweite Quartal 2023 mit Rekordzahlen bei der Quartalsproduktion und dem bereinigten Cashflow
CALGARY, ALBERTA - 14. August 2023 / IRW-Press / Saturn Oil & Gas Inc. (TSX: SOIL) (FWB: SMKA) (OTCQX: OILSF) („Saturn“ oder das „Unternehmen“) freut sich, seine Finanz- und
![Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush: https://www.marketbeat.com/logos/articles/med_20230724072744_lilly-shares-up-on-versanis-deal-amid-weight-loss.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMXRZYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--b9f83eb09fecce9f51f50355f2bfdb6f72cf87cc/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230724072744_lilly-shares-up-on-versanis-deal-amid-weight-loss.jpg?locale=us)
Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush
Shares of Eli Lilly & Co. (NYSE: LLY) closed 2.80% higher for the week ended July 21, a week after Lilly said it would buy Versanis, a privately held clinical-stage biopharmaceutical company